Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients

The current status and review of literature

Aslı Çiftçibaşı Örmeci, Çağla Yıldız, Behnam Seberi, Merve Gürakar, Cem Şimşek, Ahmet Gurakar

Research output: Contribution to journalReview article

Abstract

Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally. However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list, which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and in recent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have been transplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought new treatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to review the current literature on this evolving topic.

Original languageEnglish (US)
Pages (from-to)771-775
Number of pages5
JournalThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
Volume30
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Liver Transplantation
Transplantation
Antiviral Agents
End Stage Liver Disease
Waiting Lists
Hepatitis C
Patient Selection
Therapeutics
Transplants
Liver
Infection
Sustained Virologic Response

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients : The current status and review of literature. / Çiftçibaşı Örmeci, Aslı; Yıldız, Çağla; Seberi, Behnam; Gürakar, Merve; Şimşek, Cem; Gurakar, Ahmet.

In: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, Vol. 30, No. 9, 01.09.2019, p. 771-775.

Research output: Contribution to journalReview article

@article{672b4612063343968b794601ec923d4d,
title = "Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature",
abstract = "Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally. However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list, which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and in recent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have been transplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought new treatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to review the current literature on this evolving topic.",
author = "{{\cC}ift{\cc}ibaşı {\"O}rmeci}, Aslı and {\cC}ağla Yıldız and Behnam Seberi and Merve G{\"u}rakar and Cem Şimşek and Ahmet Gurakar",
year = "2019",
month = "9",
day = "1",
doi = "10.5152/tjg.2019.18656",
language = "English (US)",
volume = "30",
pages = "771--775",
journal = "Turkish Journal of Gastroenterology",
issn = "1300-4948",
publisher = "Turkish Society of Gastroenterology",
number = "9",

}

TY - JOUR

T1 - Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients

T2 - The current status and review of literature

AU - Çiftçibaşı Örmeci, Aslı

AU - Yıldız, Çağla

AU - Seberi, Behnam

AU - Gürakar, Merve

AU - Şimşek, Cem

AU - Gurakar, Ahmet

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally. However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list, which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and in recent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have been transplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought new treatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to review the current literature on this evolving topic.

AB - Liver transplantation is the main curative therapy for end-stage liver disease. The number of transplanted organs is increasing globally. However, the number of available organs in the pool is insufficient, considering the excessive number of patients on the waiting list, which is a major concern for transplant programs. Hepatitis C infection (HCV) is a common indication for liver transplantation, and in recent years, a major progress has been made in its treatment with direct-acting antiviral (DAA) agents. HCV-positive livers have been transplanted to HCV-positive recipients for a long time. The high rate of sustained virologic response through DAA has brought new treatment options for the patients during the pre- and post-transplantation periods. Recently, there have been few reports of transplanting the available HCV-positive organs to HCV noninfected recipients. However, there is not yet an agreement on the optimal selection of patients who would benefit from such transplantation, and this has become a current topic of interest. Thus, we aim to review the current literature on this evolving topic.

UR - http://www.scopus.com/inward/record.url?scp=85072278962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072278962&partnerID=8YFLogxK

U2 - 10.5152/tjg.2019.18656

DO - 10.5152/tjg.2019.18656

M3 - Review article

VL - 30

SP - 771

EP - 775

JO - Turkish Journal of Gastroenterology

JF - Turkish Journal of Gastroenterology

SN - 1300-4948

IS - 9

ER -